Tumor volumes were observed to be invariable across the treatment groups (Fig. S9G), but we observed a significant decrease (p < 0.0001) in the prevalence of lung metastasis in anti-LILRB4-antibody-treated mice under CRD (Fig. 6H, I). Here, LILRB4 is linked to neoplasm.